Specific determination in hepatobiliary disease drugs at smart point-of-care testing by computational chemistry-assisted molecularly imprinted electrochemical sensor | Synapse
March 3, 2026
Specific determination in hepatobiliary disease drugs at smart point-of-care testing by computational chemistry-assisted molecularly imprinted electrochemical sensor
Key Points
Effective determination of drugs for hepatobiliary disease shows high accuracy, with up to 95% specificity observed during testing.
Sensor technology utilized in this analysis integrates molecularly imprinted polymers for improved drug detection quality.
Assessment using computational chemistry-assisted methods enhances the reliability of electrochemical sensors and their applications.
This innovation supports further development of point-of-care testing, making it more accessible for clinical use in hepatobiliary conditions.